At the same time the stock seemed like a good buy partly because its shares seemed to be oversold, driven down by the prospect of increasing competition, a slight loss in market share and a Securities and Exchange Commission inquiry into revenue recognition errors.
The FDA will take new steps to track exactly what kinds of mistakes happen and will commission new studies to get a clear picture of which drugs are most involved in errors.